A5088335925- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- DNA Repair Mechanisms
- BRCA gene mutations in cancer
- Molecular Biology Techniques and Applications
- Science, Research, and Medicine
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- Chronic Lymphocytic Leukemia Research
- Genetics, Bioinformatics, and Biomedical Research
- Economic and Financial Impacts of Cancer
- Single-cell and spatial transcriptomics
Institute of Cancer Research
2022-2024
Royal Marsden Hospital
2022-2024
Breast Cancer Now
2022-2024
1010 Background: Circulating tumor DNA (ctDNA) based detection of Molecular Residual Disease (MRD) in breast cancer patients presents a strategy to identify at high risk relapse, although current assays have limited sensitivity for low level ctDNA detection. In this study we profile early with an ultra-sensitive, whole genome sequencing-based, tumor-informed platform, and correlate the findings clinical outcomes. Methods: We analysed 598 plasma samples (median 8 samples/patient, range 2-14)...
Abstract Purpose: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk relapse, yet the optimal assay ctDNA detection unknown. Experimental Design: The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays molecular residual disease (MRD) triple-negative cancer. We compared dPCR personalized multimutation sequencing 141 from cTRAK-TN. Results: MRD was first detected by...
Abstract Purpose: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 may benefit from PARP inhibitor treatment. inhibitors also increase exogenous replication stress thereby sensitivity ataxia telangiectasia Rad3-related (ATR) protein. This phase II study examined the activity combination inhibitor, olaparib, ATR ceralasertib (AZD6738), patients with advanced TNBC. Patients Methods: TNBC on most recent biopsy who had received 1 or...
Detection of molecular residual disease (MRD) allows for the identification breast cancer patients at high-risk recurrence, with potential that early initiation treatment stages relapse could improve patient outcomes. The Invitae Personalized Cancer Monitoring™ assay (PCM) is a newly developed next-generation sequencing approach utilizes up to 50 patient-specific, tumor-informed DNA variants, detect circulating tumor (ctDNA). ability PCM MRD before clinical was evaluated. cohort included 61...
Abstract Background CDK4/6 inhibitors may trigger anti-tumour immunity, both through tumour cell intrinsic and extrinsic mechanisms, which can be enhanced by immune checkpoint blockade in pre-clinical studies. Although most triple negative breast cancers (TNBC) are resistant to inhibition, palbociclib (palbo) has activity models of the luminal androgen receptor (LAR) subtype. Here we report dose finding phase Ib cohort A PAveMenT trial combining avelumab Methods The 1b consists a (cohort A),...
Abstract Introduction: Identification of Molecular Residual Disease (MRD) in patients with breast cancer circulating tumor DNA (ctDNA) presents a strategy to identify at high risk relapse. Approaches that detect ctDNA lower concentrations are required increase sensitivity and improve on the lead time between detection clinical Here we present results using novel highly sensitive tumor-informed sequencing assays for MRD based multiple patient specific mutations ctDNA. Methods: 62 stage II-III...
Abstract Background: Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage breast cancer is associated with a high risk future relapse. Identifying those at subsequent relapse may allow tailoring further therapy to delay or prevent recurrence. Previous analysis this cohort showed that tools capable detecting ctDNA lower concentrations are needed increase sensitivity and lengthen the lead time between detection We compared via personalised...
<p>Correlation between the tumor fraction percentage as reported by mean Variant Allele Frequency (mean VAF) or estimated (eVAF) for RaDaR ctDNA assay.</p>
<div>AbstractPurpose:<p>Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk relapse, yet the optimal assay ctDNA detection unknown.</p>Experimental Design:<p>The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays molecular residual disease (MRD) triple-negative cancer. We compared dPCR personalized multimutation sequencing 141 from...
<div>AbstractPurpose:<p>Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk relapse, yet the optimal assay ctDNA detection unknown.</p>Experimental Design:<p>The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays molecular residual disease (MRD) triple-negative cancer. We compared dPCR personalized multimutation sequencing 141 from...
<p>Comparison of median lead time from ctDNA detection to relapse between dPCR and RaDaR assays using paired data in all individuals with (n=40).</p>
<p>Correlation between the tumor fraction percentage as reported by mean Variant Allele Frequency (mean VAF) or estimated (eVAF) for RaDaR ctDNA assay.</p>
<p>Comparison of median lead time from ctDNA detection to relapse between dPCR and RaDaR assays using paired data in all individuals with (n=40).</p>